Tag: LLY
-
3 High-Yield Dividend ETFs to Consider for Retirement Income
Here are three dividend ETFs to consider for a retirement portfolio, each with a different approach to income, diversification, and growth.
-
Anthropic IPO Excitement Puts IPO Investing Back in Focus
A potential Anthropic IPO is tempting investors, but a better option may be an ETF that specializes in IPOs.
-
Viking Therapeutics’ Weight-Loss Drug Shows Substantial Promise
Even weekly weight loss injections can become difficult to fit into everyday life. New results from Viking Therapeutics may solve that problem.
-
2 Pharmaceutical Stocks Positioned for the Next Growth Cycle
For investors willing to look past the GLP-1 spotlight, MRK and ABBV offer exposure to the next chapter in pharmaceutical stocks,
-
Three Exchange-Traded Funds (ETFs) to Consider for the Rest of 2026
Not every income fund works the same way; the following three ETFs offer distinctly different approaches.
-
Eli Lilly’s Weight-Loss Boom Could Have Powerful Growth Ahead
Eli Lilly’s weight-loss rally has already been extraordinary, but its next stage of growth may be just beginning.
-
Volatility-Proof Income: Dividend ETFs With Steady Payouts
Dividend ETFs can provide stability by delivering regular payouts and offering exposure to quality companies with proven track records.
-
3 Blue-Chip Stocks to Help Investors Survive Potential Stagflation
Blue-chip stocks with defensive earnings drivers tend to hold up better than cyclical names when inflation and slow growth coincide.
-
FDA PreCheck Boosts Eli Lilly, Regeneron: One Stock Stands Out
Eli Lilly and Regeneron were selected for the FDA’s PreCheck pilot program, which could become a tailwind for pharmaceutical manufacturers.
-
3 High P/E Stocks Worth Buying for the Long Haul
High P/E stocks are still worth buying if earnings growth is outrunning their valuation. For these stocks, a premium multiple won’t stay premium for long.